Positive PhIII PONV study brings little Acacia to a crossroads

John Carroll Acacia Pharma says it gleaned positive results from a Phase III study of its experimental therapy designed to prevent postoperative nausea and vomiting. And now it's ...

Sunesis shares crushed in a rout after leukemia PhIII ends in defeat

John Carroll Shares of South San Francisco-based Sunesis were crushed this morning after the biotech put out word that its drug vosaroxin had flunked a Phase III test for acute myeloid ...

Karolinska Development’s CEO leaves, Erytech hits PhIII endpoints, VBL belatedly nails IPO

Nick Paul Taylor Welcome to the latest edition of our weekly EuroBiotech Report. FierceBiotech News

Regado slashes staff to preserve cash following PhIII fiasco

John Carroll Regado had all of its eggs in one basket when it took its lead therapy into a Phase III trial on its own. And now that the anticoagulant study has been shelved after signs ...

Novartis’ LCZ696 kindles megablockbuster projections with impressive PhIII heart data

John Carroll Novartis told the world back in March that its experimental heart drug LCZ696 had delivered the goods early in a pivotal study, allowing for a quick wrap of the Phase III ...

Puma shares triple on positive PhIII neratinib data, plans to file for approval

John Carroll FierceBiotech News

Shire laments hole in EU food chain, Late-stage hit for GSK & Genmab, Lundbeck drug flunks PhIII

Nick Paul Taylor Welcome to the latest edition of our weekly EuroBiotech Report. With the battle for investor support in the AbbVie-Shire takeover tug of war heating up, the Ireland-headquartered ...

Amgen, AstraZeneca score a PhIII psoriasis success with brodalumab

John Carroll After the markets closed Friday, Amgen and AstraZeneca announced that their top psoriasis contender, brodalumab, scored a win in Phase III, with a large majority of patients ...

AstraZeneca rushes immuno-oncology star into PhIII lung cancer study

John Carroll Anxious to fight off Pfizer’s $ 106 billion marriage proposal, AstraZeneca’s research team has rushed its high-profile immuno-oncology drug into a late-stage ...

GlaxoSmithKline’s darapladib team finds hope in a PhIII bomb

John Carroll No matter how badly a drug fails in Phase III, investigators and the companies that employ them often bend over backward to highlight any positive sign of efficacy, no ...

Eisai readies applications for thyroid cancer drug after SFJ delivers PhIII success

John Carroll FierceBiotech News

Astellas, Medivation’s cancer drug Xtandi scores new upbeat PhIII results

Emily Mullin Medivation and Astellas Pharma unveiled final results on primary and secondary efficacy endpoints from their Phase III PREVAIL trial of Xtandi (enzalutamide), showing that ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS